Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001213900-25-035118
Filing Date
2025-04-24
Accepted
2025-04-24 17:00:03
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 8946
2 PRESS RELEASE DATED APRIL 23, 2025 ea023939301ex1-sinovac.htm EX-1 11579
  Complete submission text file 0001213900-25-035118.txt   22275
Mailing Address NO. 39 SHANGDI XI ROAD HAIDIAN DISTRICT BEIJING F4 100085
Business Address NO. 39 SHANGDI XI ROAD HAIDIAN DISTRICT BEIJING F4 100085 86-10-82890088
SINOVAC BIOTECH LTD (Subject) CIK: 0001084201 (see all company filings)

EIN.: 000000000 | State of Incorp.: B9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-79318 | Film No.: 25868719
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 192 LYTTON AVENUE PALO ALTO CA 94301
Business Address 192 LYTTON AVENUE PALO ALTO CA 94301 650 688 0822
Vivo Capital VIII, LLC (Filed by) CIK: 0001618789 (see all company filings)

EIN.: 471761992 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A